Focus on neuromyelitis optica spectrum disorders (NMOSD) and MOG-IgG-associated diseases (MOGAD)

Prof. Dr. med. Corinna Trebst and Priv.-Doz. Dr. Martin Hümmert

The working group deals extensively with neuromyelitis optica spectrum diseases (NMOSD) and MOG-IgG associated diseases (MOGAD). These are rare autoimmune relapsing diseases of the central nervous system. As a large center of the Neuromyelitis Optica Study Group(NEMOS), we are networked throughout Germany and internationally, actively involved in the development and maintenance of the cohort study and the disease registry and participate in multicenter drug trials. Through our national (NEMOS) and European cooperation in the MOGAD Eugène Devic European Network (MEDEN), we are rapidly advancing knowledge about the two rare diseases NMOSD and MOGAD by leading and participating in numerous scientific projects. Since the foundation of the NEMOS support association, we have also taken on responsibility on the board.

Our particular research interest is the evaluation and optimization of (also experimental) forms of therapy.

In the recent past, together with 17 other NEMOS centers, we have played a leading role in investigating the effects of these diseases on quality of life and socio-economic factors(CHANCE-NMO study). A follow-up study is currently being funded by the Innovation Fund of the Federal Joint Committee (G-BA).

With the support of 17 and 12 NEMOS centers respectively, we also conducted a comprehensive study on cognition in NMOSD(CogniNMO study) and MOGAD(CogniMOG study).

Furthermore, we investigated the effects of the pandemic on rare diseases using the example of NMOSD and MOGAD(COPANMO(G) study) with 19 German and Austrian centers.

Further analyses are currently being carried out on the incidence of the disease in older people and on the burdens and possible compensation strategies of relatives of those affected.

Another focus is on the detailed characterization of AQP4-IgG positive as well as antibody-negative NMOSD and MOG-IgG associated diseases. We are also investigating possible biomarkers of disease activity, treatment response and prognosis of NMOSD and MOGAD.

 

Responsible contact persons:

Prof. Dr. Corinna Trebst(Personal Profile)
Priv.-Doz. Dr. Martin Hümmert(Personal profile)

 

Publications:

https://pubmed.ncbi.nlm.nih.gov/?term=trebst+c&sort=date

https://pubmed.ncbi.nlm.nih.gov/?term=H%C3%BCmmert+mw&sort=date

 

Further links and networks: